Evaluation of a new co-cultured Microbiome Ecosystem Therapy candidate (MaaT034) for clinical testing in combination with immune checkpoint inhibitors in solid tumors

Previous Post

October 15, 2024: MaaT Pharma Completes Recruitment of its ARES Phase 3 Trial for MaaT013 to Treat Acute Graft-versus-Host Disease